Patient-centered communication and shared decision making to reduce HbA1c levels of patients with poorly controlled type 2 diabetes mellitus - results of the cluster-randomized controlled DEBATE trial.


Journal

BMC family practice
ISSN: 1471-2296
Titre abrégé: BMC Fam Pract
Pays: England
ID NLM: 100967792

Informations de publication

Date de publication:
25 06 2019
Historique:
received: 17 09 2018
accepted: 12 06 2019
entrez: 27 6 2019
pubmed: 27 6 2019
medline: 26 2 2020
Statut: epublish

Résumé

Does an intervention designed to foster patient-centered communication and shared decision making among GPs and their patients with poorly controlled type 2 diabetes mellitus reduce the level of HbA1c. The DEBATE trial is a cluster-randomized controlled trial conducted in German primary care and including patients with type 2 diabetes mellitus having an HbA1c level of 8.0% (64 mmol/mol) or above at the time of recruitment. Data was measured before intervention (baseline, T0), 6-8 months (T1), 12-14 months (T2), 18-20 months (T3), and 24-26 months (T4) after baseline. Main outcome measure is the level of HbA1c. In both, the intervention and the control group the decline of the HbA1c level from T0 to T4 was statistically significant (- 0.67% (95% CI: - 0.80,-0.54%; p < 0.0001) and - 0.64% (95% CI: - 0.78, - 0.51%; p < 0.0001), respectively). However, there was no statistically significant difference between both groups. Although the DEBATE trial was not able to confirm effectiveness of the intervention tested compared to care as usual, the results suggest that patients with poorly controlled type 2 diabetes are able to improve their blood glucose levels. This finding may encourage physicians to stay on task to regularly approach this cohort of patients. The trial was registered at ISRCTN registry under the reference ISRCTN70713571 .

Sections du résumé

BACKGROUND
Does an intervention designed to foster patient-centered communication and shared decision making among GPs and their patients with poorly controlled type 2 diabetes mellitus reduce the level of HbA1c.
METHODS
The DEBATE trial is a cluster-randomized controlled trial conducted in German primary care and including patients with type 2 diabetes mellitus having an HbA1c level of 8.0% (64 mmol/mol) or above at the time of recruitment. Data was measured before intervention (baseline, T0), 6-8 months (T1), 12-14 months (T2), 18-20 months (T3), and 24-26 months (T4) after baseline. Main outcome measure is the level of HbA1c.
RESULTS
In both, the intervention and the control group the decline of the HbA1c level from T0 to T4 was statistically significant (- 0.67% (95% CI: - 0.80,-0.54%; p < 0.0001) and - 0.64% (95% CI: - 0.78, - 0.51%; p < 0.0001), respectively). However, there was no statistically significant difference between both groups.
CONCLUSIONS
Although the DEBATE trial was not able to confirm effectiveness of the intervention tested compared to care as usual, the results suggest that patients with poorly controlled type 2 diabetes are able to improve their blood glucose levels. This finding may encourage physicians to stay on task to regularly approach this cohort of patients.
TRIAL REGISTRATION
The trial was registered at ISRCTN registry under the reference ISRCTN70713571 .

Identifiants

pubmed: 31238871
doi: 10.1186/s12875-019-0977-9
pii: 10.1186/s12875-019-0977-9
pmc: PMC6593484
doi:

Substances chimiques

Glycated Hemoglobin A 0
Hypoglycemic Agents 0
hemoglobin A1c protein, human 0

Banques de données

ISRCTN
['ISRCTN70713571']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

87

Références

BMJ Open. 2017 Aug 4;7(8):e015135
pubmed: 28780542
Patient Educ Couns. 2010 Jul;80(1):94-9
pubmed: 19879711
Diabetes Care. 1993 May;16(5):714-21
pubmed: 8495610
Diabet Med. 2003 Jun;20(6):486-90
pubmed: 12786685
J Health Soc Behav. 1999 Jun;40(2):141-58
pubmed: 10467761
Chronic Illn. 2009 Dec;5(4):268-76
pubmed: 19933249
Diabetes Care. 2000 Sep;23(9):1321-5
pubmed: 10977026
Implement Sci. 2016 Aug 08;11:114
pubmed: 27502770
Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003638
pubmed: 15846672
CMAJ. 1995 May 1;152(9):1423-33
pubmed: 7728691
JAMA. 2002 Jul 24-31;288(4):475-82
pubmed: 12132978
Diabetes Res Clin Pract. 2016 Mar;113:1-13
pubmed: 26972954
BMC Fam Pract. 2012 Aug 22;13:88
pubmed: 22913642
J Clin Nurs. 2005 Feb;14(2):195-203
pubmed: 15669928
Med Care. 2001 Aug;39(8 Suppl 2):II2-45
pubmed: 11583120
Cochrane Database Syst Rev. 2001;(1):CD001481
pubmed: 11279717
Med Care. 2009 Aug;47(8):826-34
pubmed: 19584762
BMC Fam Pract. 2018 May 2;19(1):49
pubmed: 29720083
Cochrane Database Syst Rev. 2018 Jul 19;7:CD006732
pubmed: 30025154

Auteurs

Anja Wollny (A)

Institute of General Practice, Rostock University Medical Center, Doberaner Str. 142, 18057, Rostock, Germany.

Attila Altiner (A)

Institute of General Practice, Rostock University Medical Center, Doberaner Str. 142, 18057, Rostock, Germany.

Anne Daubmann (A)

Institute of Medical Biometry and Epidemiology, Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.

Eva Drewelow (E)

Institute of General Practice, Rostock University Medical Center, Doberaner Str. 142, 18057, Rostock, Germany.

Christian Helbig (C)

Institute of General Practice, Rostock University Medical Center, Doberaner Str. 142, 18057, Rostock, Germany.

Susanne Löscher (S)

Institute of General Practice, Medical Faculty, Heinrich-Heine University Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Germany.

Michael Pentzek (M)

Institute of General Practice, Medical Faculty, Heinrich-Heine University Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Germany.

Sara Santos (S)

Institute of General Practice, Medical Faculty, Heinrich-Heine University Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Germany.

Karl Wegscheider (K)

Institute of Medical Biometry and Epidemiology, Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.

Stefan Wilm (S)

Institute of General Practice, Medical Faculty, Heinrich-Heine University Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Germany.

Christin Löffler (C)

Institute of General Practice, Rostock University Medical Center, Doberaner Str. 142, 18057, Rostock, Germany. christin.loeffler@med.uni-rostock.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH